An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 Tyrosine Kinase Inhibitors. Garcia-Gutierrez V, Hernandez-Boluda JC. Expert Review of Hematology. 2022 Jun;15(6):477-484. doi:
10.1080/17474086.2022.2080049. PMID:
35583386
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Pinana J, Rodriguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol M, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual M, Rodriguez-Fernandez A, Olave M, Cascales-Hernandez A, Gago B, Hernandez-Rivas J, Villalon L, Corona M, Roldan-Perez A, Ribes-Amoros J, Gonzalez-Santillana C, Garcia-Sanz R, Navarro D, Serrano-Lopez A, Cedillo A, Soria-Olivas E, Sureda A, Solano C. Annals of Hematology. 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. PMID: 35780254
Azacitidine vs. Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA Registry. Labrador J, Martinez-Cuadron D, de la Fuente A, Rodriguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, Lopez-Pavia M, Trigo F, Martinez-Sanchez MP, Rodriguez-Gutierrez JI, Rodriguez-Medina C, Gil C, Garcia Belmonte D, Vives S, Foncillas MA, Perez-Encinas M, Novo A, Recio I, Rodriguez-Macias G, Bergua JM, Noriega V, Lavilla E, Roldan-Perez A, Sanz MA, Montesinos P, on Behalf of Pethema Group. Cancers. 2022 May 9;14(9):2342. doi: 10.3390/cancers14092342. PMID: 35565471
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Piñana JL, Garcia-Sanz R, Martino R, Garcia-Roa M, Martin-Martin GA, Risco-Gálvez I, Tormo M, Martinez-Barranco P, Marcos-Corrales S, Calabuig M, Conesa V, Teruel A, Ruiz-Pérez S, Solano C, Navarro D, Cedillo Á, Sureda A. Blood Advances. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326. PMID: 34905620
Breakthrough infections in MPN-COVID vaccinated patients. Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas M, Rumi E, Elli E, Lunghi F, Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali H, Andrade-Campos M, Palandri F, Harrison C, Foncillas M, Osorio S, Koschmieder S, Mazo E, Kiladjian J, Calderon E, Heidel F, Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez A, Hernandez-Boluda J, Abadia E, Carli G, Serrano M, Kusec R, Cirici B, Guenova M, Elorza B, Angona A, Cichocka E, de Nalecz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi A. Blood Cancer Journal. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921
Characteristics and outcomes of adult patients in the PETHEMA Registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia. Martinez-Cuadron D, Serrano J, Mariz J, Gil C, Tormo M, Martinez-Sanchez P, Rodriguez-Arboli E, Garcia-Boyero R, Rodriguez-Medina C, Martinez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Espadana A, Sayas M, Algarra L, Vidriales M, Vasconcelos G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Chillon M, Rodriguez-Gutierrez J, Calasanz M, Labrador J, Lopez J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Barragan E, Sanz M, Montesinos P. Cancers. 2022 Jun 6;14(11):2817. doi: 10.3390/cancers14112817. PMID: 35681796
Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Velez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martinez C, Perez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A. Annals of Hematology. 2022 Dec;101(12):2819-2820. doi: 10.1007/s00277-022-05005-4. PMID: 36264368
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden J, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Bone Marrow Transplantation. 2022 Jun;57(6):1051. doi: 10.1038/s41409-022-01652-3. PMID: 35361897
Determinants of early triage for hospitalization in MPN patients with COVID-19. Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Calderon E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. American Journal of Hematology. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. PMID: 36111658
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Bataller A, Garrido A, Guijarro F, Onate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, de Llano M, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guinon A, Salamero O, Sampol A, Merchan B, Bargay J, Castano-Diez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, Lopez-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu J, Colomer D, Brunet S, Sierra J, Esteve J. Blood advances. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. PMID: 34911079
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jimenez A, Brunet S, Casano J, Oiartzabal I, Diez-Campelo M, Ramos F, Romero R, Salido-Fierrez E, Pedro C, Bargay J, Munoz-Novas C, Lopez R, Rafel M, Valcarcel D. Leukemia & Lymphoma. 2022 Dec 28;1-12. doi: 10.1080/10428194.2022.2154604. PMID: 36577016
How I manage myeloproliferative neoplasm-unclassifiable: practical approaches for 2022 and beyond. McLornan D, Hargreaves R, Hernandez-Boluda J, Harrison C. British Journal of Haematology. 2022 May;197(4):407-416. doi: 10.1111/bjh.18087. PMID: 35191542
Impact of center-related characteristics and macroeconomic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with pediatric-inspired protocols. Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, Garcia-Cadenas I, Queipo de Llano MP, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM. Hemasphere. 2022 Dec 23;7(1):e810. doi: 10.1097/HS9.0000000000000810. PMID: 36583094
Impact of donor-derived CD34+infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. Czerw T, Iacobelli S, Malpassuti V, Koster L, Kroeger N, Robin M, Maertens J, Chevallier P, Watz E, Poire X, Snowden JA, Kuball J, Kinsella F, Blaise D, Remenyi P, Mear JB, Cammenga J, Rubio MT, Maury S, Daguindau E, Finnegan D, Hayden P, Hernandez-Boluda JC, McLornan D, Yakoub-Agha I. Bone Marrow Transplantation. 2022 Feb;57(2):261-270. doi: 10.1038/s41409-021-01540-2. PMID: 34853433
Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA Registry Study. Ayala R, Carreno-Tarragona G, Barragan E, Boluda B, Larrayoz M, Chillon M, Carrillo-Cruz E, Bilbao C, Sanchez-Garcia J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Perez-Simon J, Calbacho M, Alonso-Dominguez J, Labrador J, Tormo M, Amigo M, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz M, Gomez-Casares T, Garcia-Sanz R, Sanz M, Martinez-Lopez J, Montesinos P. Cancers. 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799. PMID: 36497281
Impact of individual comorbidities on survival of patients with myelofibrosis. García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, García-Hernández MC, Gómez-Casares MT, Ferrer-Marín F, Saavedra S, Cervantes F, García-Delgado R. Cancers. 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331. PMID: 35565461
Impact of molecular profiling on the management of patients with myelofibrosis. Pastor-Galan I, Martin I, Ferrer B, Hernandez-Boluda J. Cancer Treatment Reviews. 2022 Jul 8;109:102435. doi: 10.1016/j.ctrv.2022.102435. PMID: 35839532
Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Guijarro F, Bataller A, Diaz-Beya M, Garrido A, Coll-Ferra C, Vives S, Salamero O, Valcarcel D, Tormo M, Arnan M, Sampol A, Castano-Diez S, Martinez C, Suarez-Lledo M, Fernandez-Aviles F, Hernandez-Boluda J, Ribera J, Rovira M, Brunet S, Sierra J, Esteve J. Bone Marrow Transplantation. 2022 Aug;57(8):1304-1312. doi: 10.1038/s41409-022-01703-9. PMID: 35643942
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Velez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martinez C, Perez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A. Annals of Hematology. 2022 Oct;101(10):2231-2239. doi: 10.1007/s00277-022-04963-z. PMID: 36042023
Machine learning improves risk stratification in myelofibrosis: an analysis of the Spanish registry of myelofibrosis. Mosquera-Orgueira A, Perez-Encinas M, Hernandez-Sanchez A, Gonzalez-Martinez T, Arellano-Rodrigo E, Martinez-Elicegui J, Villaverde-Ramiro A, Raya JM, Ayala R, Ferrer-Marin F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Angona A, Cuevas B, Senin MA, Ramirez-Payer A, Ramirez MJ, Perez-Lopez R, Gonzalez de Villambrosia S, Martinez-Valverde C, Gomez-Casares MT, Garcia-Hernandez C, Gasior M, Bellosillo B, Steegmann JL, Alvarez-Larran A, Hernandez-Rivas JM, Hernandez-Boluda JC. Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. PMID: 36570691
Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. Torres I, Huntley D, Tormo M, Calabuig M, Hernandez-Boluda J, Terol M, Carretero C, de Michelena P, Perez A, Pinana J, Colomina J, Solano C, Navarro D. BMC Infectious Diseases. 2022 Feb 21;22(1):172. doi: 10.1186/s12879-022-07154-3. PMID: 35189833
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: a retrospective study by the chronic malignancies working party of the EBMT. McLornan D, Gras L, Martin I, Sirait T, Schroeder T, Blau I, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifon J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden P, Czerw T, Hernandez-Boluda J, Yakoub-Agha I. British Journal of Haematology. 2022 Jul;198(1):209-213. doi: 10.1111/bjh.18219. PMID: 35482558
Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: a combined CIBMTR/CMWP of EBMT analysis. Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernandez-Boluda J, Czerw T, Hayden P, Kansagra A, Ho V, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani B, McLornan D, Yakoub-Agha I, Saber W. British Journal of Haematology. 2022 Aug;198(4):785-789. doi: 10.1111/bjh.18297. PMID: 35658101
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Sangerman M, Moreno A, Quintana A, Garcia-Vidal C, Rubio M, Diaz M, Vendranas M, Macias G. Expert Review of Hematology. 2022 Mar;15(3):203-214. doi: 10.1080/17474086.2022.2054801. PMID: 35332831
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. Hernandez-Boluda JC, Pastor-Galan I, Arellano-Rodrigo E, Raya JM, Perez-Encinas M, Ayala R, Ferrer-Marin F, Velez P, Mora E, Fox ML, Hernandez-Rivas JM, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Perez-Lopez R, Angona A, Cuevas B, Senin A, Ramirez MJ, Ramirez-Payer A, Gomez-Casares MT, Martinez-Valverde C, Magro E, Steegmann JL, Duran MA, Garcia-Hernandez C, Gasior M, de Villambrosia S, Alvarez-Larran A, Pereira A. British Journal of Haematology. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. PMID: 36089912
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Ribera J, Granada I, Morgades M, Gonzalez T, Ciudad J, Such E, Calasanz M, Mercadal S, Coll R, Gonzalez-Campos J, Tormo M, Garcia-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermudez A, Orfao A, Ribera J, Programa Tratamiento Hemopatias Ma, Spanish Soc Hematology, SEHH. British Journal of Haematology. 2022 Feb;196(3):670-675. doi: 10.1111/bjh.17844. PMID: 34549416
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Blood Advances. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. PMID: 34516636
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Luna A, Perez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuno C, Vega M, Alvarez-Larran A, Salamanca A, Garcia-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Perez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jimenez-Velasco A, Lakhwani S, Casado L, Rosell A, Escola A, Fernandez M, Garcia-Hernandez C, Cervero C, Mora E, Sagues M, Suarez-Varela S, Velez P, Carrascosa Mastell P, Bitaube R, Serrano L, Cortes M, Vera Goni J, Steegmann J, de Soria V, Alonso-Dominguez J, Araujo M, Coll A, Hernandez-Boluda J, Garcia-Gutierrez V. Annals of Hematology. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. PMID: 35997804
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Alvarez-Larran A, Garrote M, Ferrer-Marin F, Perez-Encinas M, Mata-Vazquez M, Bellosillo B, Arellano-Rodrigo E, Gomez M, Garcia R, Garcia-Gutierrez V, Gasior M, Cuevas B, Angona A, Gomez-Casares M, Martinez C, Magro E, Ayala R, del Orbe-Barreto R, Perez-Lopez R, Fox M, Raya J, Guerrero L, Garcia-Hernandez C, Caballero G, Murillo I, Xicoy B, Ramirez M, Carreno-Tarragona G, Hernandez-Boluda J, Pereira A. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. PMID: 35417564
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. Vilorio-Marques L, Fernandez CC, Mora E, Gutierrez L; Rey Bua B, Jimenez Lorenzo MJ, Diaz Beya M, Vara Pampliega M, Molero A, Sanchez-Garcia J, Calabuig M, Cedena MT, Chen-Liang T, Diaz Santa JA, Padilla I, Hernandez F, Diez R, Asensi P, Xicoy B, Sanz G, Valcarcel D, Diez-Campelo M, Bernal T. Therapeutic Advances in Hematology. 2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. PMID: 36199837
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. Triguero A, Xicoy B, Zamora L, Jimenez M, Garcia O, Calabuig M, Diaz-Beya M, Arzuaga J, Ramos F, Medina A, Bernal T, Talarn C, Coll R, Collado R, Chen T, Borras J, Brunet S, Marchante I, Marco V, Lopez-Cadenas F, Calbacho M, Simiele A, Cortes M, Cedena M, Pedreno M, Aguilar C, Pedro C, Fernandez M, Stoica C, Ribera J, Sanz G. Leukemia Research. 2022 May;116:106836. doi: 10.1016/j.leukres.2022.106836. PMID: 35405632
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Pinana JL, Lopez-Corral L, Martino R, Vazquez L, Perez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, Corona M, Marcos-Corrales S, Tormo M, Hernandez-Rivas JA, Montoro J, Rodriguez-Fernandez A, Risco-Galvez I, Rodriguez-Belenguer P, Hernandez-Boluda JC, Garcia-Cadenas I, Ruiz-Garcia M, Munoz-Bellido JL, Solano C, Cedillo A, Sureda A, Navarro D. Journal of Hematology & Oncology. 2022 May 7;15(1):54. doi: 10.1186/s13045-022-01275-7. PMID: 35526045
Second versus first wave of COVID-19 in patients with MPN. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas M, Elli E, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Kabat M, Cuevas B, Fox M, Andrade-Campos M, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas M, Bonifacio M, Alvarez-Larran A, Kiladjian J, Calderon E, Patriarca A, Cervantes K, Griessammer M, Garcia-Gutierrez V, Sanchez A, Mazo E, Ruggeri M, Hernandez-Boluda J, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi A. Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. PMID: 35064223
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Pinana J, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez-Veiga R, Garrido A, Sierra J, Ribera J, Torrent A, Mateos M, de la Rubia J, Tormo M, Diez-Campelo M, Garcia-Gutierrez V, Alvarez-Larran A, Sancho J, MartinGarcia-Sancho A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernandez-Rivas J, Cedillo A, Garcia-Sanz R, Bosch F. Leukemia & Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. PMID: 34668835
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients. Villar S, Ariceta B, Agirre X, Urribarri A, Ayala R, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Simoes C, Herrera P, Calasanz M, Alfonso-Pierola A, Paiva B, Martinez-Lopez J, San Miguel J, Prosper F, Montesinos P. Frontiers in Oncology. 2022 Nov 24;12:1054458. doi: 10.3389/fonc.2022.1054458. PMID: 36505804
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Martinez-Cuadron D, Megias-Vericat JE, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C, Aguiar E, Bergua Burgues JM, Lopez-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodriguez-Medina C, Lopez-Pavia M, Tormo M, Algarra JL, Amigo ML, Sayas MJ, Labrador J, Rodriguez-Gutierrez JI, Benavente C, Costilla-Barriga L, Garcia-Boyero R, Lavilla E, Vives S, Herrera P, Garcia D, Herraez-Albendea MM, Esteves GV, Gomez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MA, Montesinos P. Blood Advances. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. PMID: 34794172
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Labrador J, Saiz-Rodriguez M, de Miguel D, de Laiglesia A, Rodriguez-Medina C, Vidriales M, Perez-Encinas M, Sanchez-Sanchez M, Cuello R, Roldan-Perez A, Vives S, Benzo-Callejo G, Colorado M, Garcia-Fortes M, Sayas M, Olivier C, Recio I, Conde-Royo D, Bienert-Garcia A, Vahi M, Munoz-Garcia C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas M, Martinez-Cuadron D, Sanz M, Montesinos P. Cancers. 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734. PMID: 35406512